0001213900-24-096811 | 10-Q | XBRL Viewer

Income Taxes	9 Months Ended
Sep. 30, 2024
Income Taxes [Abstract]
Income taxes	9. Income taxes We do not expect to pay any significant federal or state income taxes as a result of (i) the losses recorded during the three and nine months ended September 30, 2024 and 2023, (ii) additional losses expected for the remainder of 2024 or losses recorded in 2023, or (iii) net operating loss carry forwards from prior years. We recorded a full valuation allowance of the net operating losses for the three and nine months ended September 30, 2024 and 2023. Accordingly, there were no provisions for income taxes for the three and nine months ended September 30, 2024 and 2023. Additionally, as of September 30, 2024 and December 31, 2023, we maintain a full valuation allowance for all deferred tax assets.

Income Taxes

9 Months Ended

Sep. 30, 2024

9. Income taxes

We do not expect to pay any significant federal or state income taxes as a result of (i) the losses recorded during the three and nine months ended September 30, 2024 and 2023, (ii) additional losses expected for the remainder of 2024 or losses recorded in 2023, or (iii) net operating loss carry forwards from prior years.

We recorded a full valuation allowance of the net operating losses for the three and nine months ended September 30, 2024 and 2023. Accordingly, there were no provisions for income taxes for the three and nine months ended September 30, 2024 and 2023. Additionally, as of September 30, 2024 and December 31, 2023, we maintain a full valuation allowance for all deferred tax assets.

- Definition

The entire disclosure for income tax.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477891/740-270-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-13

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/740/tableOfContent

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-14

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-21

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-17

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482603/740-30-50-2

+ Details

Licensed Rights and Other Intangible Assets (Tables)

9 Months Ended

Sep. 30, 2024

Licensed Rights and Other Intangible Assets [Abstract]

Schedule of License Rights and Other Intangible Assets, Net

The following provides information about our license rights and other intangible assets, net as of September 30, 2024 and December 31, 2023 (in thousands):

	September 30, 2024						December 31, 2023
	Gross Carrying Amount		Accumulated Amortization		Net		Gross Carrying Amount		Accumulated Amortization		Net
Intangible assets subject to amortization:
Hormone therapy drug patents	$	5,753	$	1,957	$	3,796	$	6,818	$	1,871	$	4,947
Hormone therapy drug patents applied and pending approval		323		—		323		842		—		842
Intangible assets subject to amortization		6,076		1,957		4,119		7,660		1,871		5,789
Intangible assets not subject to amortization:
Trademarks/trade name rights		309		—		309		309		—		309
License rights and other intangible assets, net	$	6,385	$	1,957	$	4,428	$	7,969	$	1,871	$	6,098

Schedule of Intangible Assets Subject to Amortization

Our intangible assets subject to amortization are expected to be amortized as follows (in thousands):

Year ending December 31,
2024	$	97
2025		384
2026		384
2027		384
2028		384
Thereafter		2,163
Total	$	3,796

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Cash flows from operating activities:
Net loss	$ (2,433)	$ (9,395)
Less: Loss from discontinued operations, net of income taxes	(7)	(3,237)
Net loss from continuing operations	(2,426)	(6,158)
Adjustments to reconcile net loss to net cash provided by (used in) continuing operating activities:
Depreciation and amortization	409	285
Impairment of long-lived assets (Note 4)	1,261
Write-off of patents and trademarks		59
Share-based compensation	240	1,155
Other	572	525
Changes in operating assets and liabilities:
Other assets	1,874	1,185
Prepaid and other current assets	17	(1,241)
Accounts payable	207	(1,466)
Accrued expenses and other current liabilities	(315)	(11,918)
Lease liabilities	(755)	(629)
Other non-current liabilities	69	82
Total adjustments	3,579	(11,963)
Net cash provided by (used in) continuing operating activities	1,153	(18,121)
Cash flows from financing activities:
Proceeds from sale of common stock, net of costs		1,149
Net cash provided by continuing financing activities	0	1,149
Discontinued operations:
Net cash used in operating activities	(433)	(22,179)
Net cash used in discontinued operations	(433)	(22,179)
Net increase (decrease) in cash	720	(39,151)
Cash and cash equivalents - continuing operations, beginning of period	4,327	49,317
Total cash and cash equivalents, end of period	$ 5,047	$ 10,166

Accounting Policies, by Policy (Policies)

9 Months Ended

Sep. 30, 2024

Accounting Policies [Abstract]

General

General

TherapeuticsMD, Inc. (the “Company”), a Nevada corporation, and its condensed consolidated subsidiaries are referred to collectively in this Quarterly Report on Form 10-Q (“10-Q Report”) as “TherapeuticsMD,” “we,” “our” and “us.” This 10-Q Report includes trademarks, trade names and service marks, such as TherapeuticsMD®, vitaMedMD®, BocaGreenMD® , IMVEXXY®, and BIJUVA®, which are protected under applicable intellectual property laws and are the property of, or licensed by or to, us. Solely for convenience, trademarks, trade names and service marks referred to in this 10-Q Report may appear without the ®, TM or SM symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the right of the applicable licensor to these trademarks, trade names and service marks. We do not intend our use or display of other parties’ trademarks, trade names or service marks to imply, and such use or display should not be construed to imply a relationship with, or endorsement or sponsorship of us by, these other parties.

TherapeuticsMD was previously a women’s healthcare company with a mission of creating and commercializing innovative products to support the lifespan of women from pregnancy prevention through menopause. In December 2022, we changed our business to become a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. On December 30, 2022 (the “Closing Date”), we completed a transaction (the “Mayne Transaction”) with Mayne Pharma LLC, a Delaware limited liability company (“Mayne Pharma”) and subsidiary of Mayne Pharma Group Limited, an Australian public company, in which we and our subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize our IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the “Licensed Products”) in the United States and its possessions and territories, (ii) assigned to Mayne Pharma our exclusive license to commercialize ANNOVERA® (together with the Licensed Products, collectively, the “Products”) in the United States and its possessions and territories, and (iii) sold certain other assets to Mayne Pharma in connection therewith.

In a License Agreement, dated December 4, 2022, between TherapeuticsMD and Mayne Pharma (the “Mayne License Agreement”), we granted Mayne Pharma, on the Closing Date, (i) an exclusive, sublicensable, perpetual, irrevocable license to research, develop, register, manufacture, have manufactured, market, sell, use, and commercialize the Licensed Products in the United States and its possessions and territories and (ii) an exclusive, sublicensable, perpetual, irrevocable license to manufacture, have manufactured, import and have imported the Licensed Products outside the United States for commercialization in the United States and its possessions and territories.

Under the Mayne License Agreement, Mayne Pharma will pay us milestone payments of each of (i) $5.0 million if aggregate net sales of all Products in the United States during a calendar year reach $100.0 million, (ii) $10.0 million if aggregate net sales of all Products in the United States during a calendar year reach $200.0 million and (iii) $15.0 million if aggregate net sales of all Products in the United States during a calendar year reach $300.0 million. Further, Mayne Pharma will pay us royalties on net sales of all Products in the United States at a royalty rate of 8.0% on the first $80.0 million in annual net sales and 7.5% on annual net sales above $80.0 million, subject to certain adjustments, for a period of 20 years following the Closing Date. The royalty rate will decrease to 2.0% on a Product-by-Product basis upon the earlier to occur of (i) the expiration or revocation of the last patent covering a Product and (ii) a generic version of a Product launching in the United States. Mayne Pharma will pay us minimal annual royalties of $3.0 million per year for 12 years, adjusted for inflation at an annual rate of 3%, subject to certain further adjustments, including as described below. Upon the expiry of the 20-year royalty term, the licenses granted to Mayne Pharma under the Mayne License Agreement will become a fully paid-up and royalty free license for the Licensed Products.

Under the Transaction Agreement, dated December 4, 2022, between TherapeuticsMD and Mayne Pharma (the “Transaction Agreement”), we sold to Mayne Pharma, at closing, certain assets for Mayne Pharma to commercialize the Products in the United States, including, with the Population Council’s consent, our exclusive license from the Population Council to commercialize ANNOVERA (the “Transferred Assets”).

The total consideration from Mayne Pharma to TherapeuticsMD for the purchase of the Transferred Assets and the grant of the licenses under the Mayne Transaction Agreement was (i) a cash payment of $140.0 million at closing, (ii) a cash payment of approximately $12.1 million at closing for the acquisition of net working capital as determined in accordance with the Transaction Agreement and subject to certain adjustments, (iii) a cash payment of approximately $1.0 million at closing for prepaid royalties in connection with the Mayne License Agreement Amendment (as defined below) and (iv) the right to receive the contingent consideration set forth in the Mayne License Agreement, as amended. The acquisition of net working capital was determined in accordance with the Transaction Agreement and included significant estimates which could change materially for a period of up to two years following the Closing Date.

On the Closing Date, TherapeuticsMD and Mayne Pharma entered into Amendment No. 1 to the Mayne License Agreement (the “Mayne License Agreement Amendment”). Pursuant to the Mayne License Agreement Amendment, Mayne Pharma agreed to pay us approximately $1.0 million in prepaid royalties on the Closing Date. The prepaid royalties reduced the first four quarterly payments that would have otherwise been payable pursuant to the Mayne License Agreement by an amount equal to $257 thousand per quarterly royalty payment plus interest calculated at 19% per annum accruing from the Closing Date until the date such quarterly royalty payment was paid to us. We and Mayne Pharma settled the $1.5 million of consideration due to Mayne Pharma for the assumed obligations under a long-term services agreement, including our minimum payment obligations thereunder. As the parties agreed, during the second quarter of 2023 Mayne Pharma held back our royalty payment of $0.6 million and we funded an additional $0.9 million in August 2023 to settle the original $1.5 million payable.

As part of the transformation that included the Mayne License Agreement, historical results of commercial operations for all periods prior to the Closing Date have been reflected as discontinued operations in our condensed consolidated financial statements. Assets and liabilities associated with the commercial business are classified as assets and liabilities of discontinued operations in our condensed consolidated balance sheets. Additional disclosures regarding discontinued operations are provided in Note 2 of our condensed consolidated financial statements.

We also have license agreements with strategic partners to commercialize IMVEXXY and BIJUVA outside of the U.S.

●

In July 2018, we entered into a license and supply agreement (the “Knight License Agreement”) with Knight Therapeutics Inc. (“Knight”) pursuant to which we granted Knight an exclusive license to commercialize IMVEXXY and BIJUVA in Canada and Israel. Knight obtained regulatory approval for IMVEXXY and BIJUVA and began commercialization efforts in 2024.

●

In September 2019, we entered into an exclusive license and supply agreement (the “Theramex License Agreement”) with Theramex HQ UK Limited (“Theramex”) to commercialize IMVEXXY and BIJUVA outside of the U.S., excluding Canada and Israel. In 2021, Theramex secured regulatory approval for BIJUVA in certain European countries and began commercialization efforts in those countries.

In connection with our transformation into a pharmaceutical royalty company, the termination of our executive management team (except for Mr. Marlan Walker, our former General Counsel and current Chief Executive Officer) and all other employees was completed by December 31, 2022. Severance obligations for all employees other than executive officers were paid in full in January 2023 and severance obligations for terminated executive officers have been paid in accordance with their employment agreements and separation agreements as previously disclosed. As of December 31, 2023 and September 30, 2024, we employed one full-time employee primarily engaged in an executive position.

We have engaged external consultants who support our relationship with current partners and assist with certain financial, legal, and regulatory matters and the continued wind-down of our historical business operations. On August 15, 2023, we entered into a master services agreement with JZ Advisory Group, pursuant to which Joseph Ziegler would serve as our Principal Financial Officer. On August 17, 2023 Michael C. Donegan notified us of his decision to resign from the positions of Principal Financial and Accounting Officer of our Company effective as of August 17, 2023. Mr. Ziegler succeeded Mr. Donegan as Principal Financial and Accounting Officer as of the date of Mr. Donegan’s resignation.

Going concern

Going concern

Following the transaction with Mayne Pharma, our primary source of revenue is from royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. We may need to raise additional capital to provide additional liquidity to fund our operations until we become cash flow positive. To address our capital needs, we may pursue various equity and debt financing and other alternatives. The equity financing alternatives may include the private placement of equity, equity-linked, or other similar instruments or obligations with one or more investors, lenders, or other institutional counterparties or an underwritten public equity or equity-linked securities offering. Our ability to sell equity securities may be limited by market conditions, including the market price of our common stock, and our available authorized shares.

To the extent that we raise additional capital through the sale of such securities, the ownership interests of our existing stockholders will be diluted, and the terms of these new securities may include liquidation or other preferences that adversely affect the rights of our existing stockholders. If we are not successful in obtaining additional financing, we could be forced to discontinue or curtail our business operations, sell assets at unfavorable prices, or merge, consolidate, or combine with a company with greater financial resources in a transaction that might be unfavorable to us.

On May 1, 2023, we entered into a Subscription Agreement (the “Subscription Agreement”) with Rubric Capital Management LP (“Rubric”), pursuant to which we agreed to sell to Rubric, or one or more of its affiliates, up to an aggregate of 5,000,000 shares of our common stock, par value $0.001 per share (our “Common Stock”), from time to time during the term of the Subscription Agreement in separate draw-downs at our election. On June 29, 2023, we issued and sold 312,525 shares of Common Stock at a price per share equal to $3.6797 pursuant to the Subscription Agreement. We received gross proceeds of $1.15 million from the draw down, before expenses. On November 15, 2023, Rubric drew down an additional 877,192 shares of Common Stock at a price per share equal to $2.2761. We received gross proceeds of $2.0 million from the drawdown, before expenses.

In February 2024, the Company received Mayne Pharma’s calculation of allowance for payer rebates and wholesale distributor fees pursuant to the Transaction Agreement which differed significantly from the Company’s estimate of the allowances. The Company intends to resolve this matter through the dispute resolution process outlined in the Transaction Agreement. The Company continues to believe its estimated allowances for payer rebates and wholesale distributor fees are reasonable. The outcome of this matter is uncertain at this point. As a result, the Company cannot reasonably estimate a range of loss, and accordingly, the Company has not accrued any additional liability associated with Mayne Pharma’s allowance calculation for payer rebates and wholesale distributor fees.

In addition, the Company has received information from Mayne Pharma pertaining to the allowance for returns that differs from the Company’s estimate of the allowance. As of September 30, 2024, the Company believes no additional accrual is required for amounts that may be owed for the allowance for returns under the Transaction Agreement, as the Company cannot reasonably estimate a range of loss. The Company has not recorded any contingent gains or receivables for any such allowances. Management continues to monitor the unresolved and pending net working capital items as changes to estimated amounts owed or amounts due from Mayne Pharma may be material.

If Mayne Pharma’s sales of Licensed Products grow more slowly than expected or decline, if the net working capital settlement with Mayne Pharma under the Transaction Agreement is greater than our current estimates, if we are unsuccessful with future financings or the supply chains related to the third-party contract manufacturers are worse than we anticipate, our existing cash reserves may be insufficient to satisfy our liquidity requirements. The potential impact of these factors in conjunction with the uncertainty of the capital markets raises substantial doubt about our ability to continue as a going concern for the next twelve months from the issuance of these financial statements.

The accompanying consolidated financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern.

Basis of presentation

Basis of presentation

We prepared the condensed consolidated financial statements included in this 10-Q Report following the requirements of the United States (“U.S.”) Securities and Exchange Commission (“SEC”) for interim reporting. As permitted under those rules, certain notes or other financial information that are normally required by accounting principles generally accepted in the U.S. (“U.S. GAAP”) for complete financial statements can be condensed or omitted. However, except as disclosed herein, there has been no material change in the information disclosed in the notes included in our 2023 Annual Report on Form 10-K (the “2023 10-K Report”).

As part of the transformation as a result of the Mayne Transaction, historical results of commercial operations for all periods prior to the Closing Date have been reflected as discontinued operations in the condensed consolidated financial statements. Assets and liabilities associated with the commercial business are classified as assets and liabilities of discontinued operations in the condensed consolidated balance sheets. Additional disclosures regarding discontinued operations are provided in Note 2 of the condensed consolidated financial statements.

Revenues, expenses, assets, liabilities, and equities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year. In our opinion, all adjustments necessary for a fair presentation of the financial statements, which are of a normal and recurring nature, have been made for the interim periods reported. The information included in this 10-Q Report should be read in conjunction with the consolidated financial statements and accompanying notes included in our 2023 10-K Report. Certain amounts in the consolidated financial statements and accompanying notes may not add due to rounding, and all percentages have been calculated using unrounded amounts. Certain prior period amounts have been reclassified to conform to current-period presentation.

New accounting standards

New accounting standards

Adoption of new accounting standards

In November 2023, the Financial Accounting Standards Board (“FASB”) issued Update 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures” (“Update 2023-07”). Update 2023-07 applies to all public entities that are required to report segment information in accordance with Topic 280. The amendments in Update 2023-07 revise reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The amendments in Update 2023-07 do not change how a public entity identifies its operating segments, aggregates those operating segments, or applies the quantitative thresholds to determine its reportable segments. Update 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. Update 2023-07 should be applied retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the impact of adopting Update 2023-07.

In December 2023, the Financial Accounting Standards Board (“FASB”) issued ASU 2023-09, “Income Taxes (Topic 740) - Improvements to Income Tax Disclosures” (“ASU 2023-09”). ASU 2023-09 enhances the transparency and decision usefulness of income tax disclosures by requiring consistent categories and greater disaggregation of information in the rate reconciliation and income taxes paid disaggregated by jurisdiction. ASU 2023-09 will be effective for the Company in its income tax disclosure included in its 2025 Annual Report on Form 10-K and will be applied on a prospective basis. However, retrospective application is permitted. Early adoption is also permitted. The Company is evaluating the impact of ASU 2023-09 on the Company’s income tax disclosures and on its consolidated financial statements.

Estimates and assumptions

Estimates and assumptions

The preparation of our condensed consolidated financial statements in conformity with U.S. GAAP requires us to make certain estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting periods. We evaluate our estimates and assumptions based on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ, at times in material amounts, from these estimates under different assumptions or conditions.

Significant accounting policies

Significant accounting policies

The significant accounting policies we use for quarterly financial reporting are disclosed in Note 1 of the notes to the consolidated financial statements included in our 2023 10-K report.

Licensed Rights and Other Intangible Assets (Details) - Schedule of Intangible Assets Subject to Amortization $ in Thousands	Sep. 30, 2024 USD ($)
Schedule of Intangible Assets Subject to Amortization [Abstract]
2024	$ 97
2025	384
2026	384
2027	384
2028	384
Thereafter	2,163
Total	$ 3,796

Business Concentrations

9 Months Ended

Sep. 30, 2024

Business Concentrations [Abstract]

Business concentrations

12. Business concentrations

TherapeuticsMD was previously a women’s healthcare company with a mission of creating and commercializing innovative products to support the lifespan of women from pregnancy prevention through menopause. In December 2022, we changed our business to become a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. As part of the transformation that included the Mayne License Agreement, historical results of commercial operations for all periods prior to the Closing Date have been reflected as discontinued operations in our condensed consolidated financial statements. Assets and liabilities associated with the commercial business are classified as assets and liabilities of discontinued operations in our condensed consolidated balance sheets. Additional disclosures regarding discontinued operations are provided in Note 2.

For the three and nine months ended September 30, 2024, 100% of license revenue related to Mayne Pharma, Theramex and Knight.

As of September 30, 2024, we had a royalty receivable of $3,323 thousand relating to the short-term portion of receivable from Mayne Pharma, Theramex and Knight and $16,610 thousand relating to the long-term portion of royalty receivable which includes royalties recognized from the minimum annual royalty that Mayne Pharma is obligated to pay to us under the Mayne License Agreement.

Stockholders’ Equity (Details) - Schedule of the Status of Our PSUs and Related Transactions - Performance Shares [Member]

9 Months Ended

Sep. 30, 2024

USD ($)

$ / shares

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Beginning Balance | shares

12,000

^[1]

Weighted Average Exercise Price, Beginning Balance | $ / shares

$ 49.36

Aggregate Intrinsic Value, Beginning Balance | $

$ 32,570

Stock Unit, Vested | shares

(7,000)

^[1]

Weighted Average Grant Date Fair Value, Vested | $ / shares

$ 60.5

Aggregate Intrinsic Value | $

$ 16,160

Ending Balance | shares

5,000

^[1]

Weighted Average Exercise Price, Ending Balance | $ / shares

$ 34.5

Aggregate Intrinsic Value, Ending Balance | $

$ 8,630

[1]	The number of PSUs represents the base number of PSUs that may vest.

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 1D
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(v)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Revenue

9 Months Ended

Sep. 30, 2024

Revenue [Abstract]

Revenue

8. Revenue

Pursuant to the Mayne License Agreement, the Company granted Mayne Pharma, on the Closing Date, (i) an exclusive, sublicensable, perpetual, irrevocable license to research, develop, register, manufacture, have manufactured, market, sell, use, and commercialize the Licensed Products in the United States and its possessions and territories and (ii) an exclusive, sublicensable, perpetual, irrevocable license to manufacture, have manufactured, import and have imported the Licensed Products outside the United States for commercialization in the United States and its possessions and territories.

Pursuant to the Mayne License Agreement, Mayne Pharma will make one-time, milestone payments to the Company of each of (i) $5.0 million if aggregate net sales of all Products in the United States during a calendar year reach $100.0 million, (ii) $10.0 million if aggregate net sales of all Products in the United States during a calendar year reach $200.0 million and (iii) $15.0 million if aggregate net sales of all Products in the United States during a calendar year reach $300.0 million. Further, Mayne Pharma will pay to the Company royalties on net sales of all Products in the United States at a royalty rate of 8.0% on the first $80 million in annual net sales and 7.5% on annual net sales above $80.0 million, subject to certain adjustments, for a period of 20 years following the Closing Date. The royalty rate will decrease to 2.0% on a Product-by-Product basis upon the earlier to occur of (i) the expiration or revocation of the last patent covering a Product and (ii) a generic version of a Product launching in the United States. Mayne Pharma will pay to the Company minimal annual royalties of $3.0 million per year for 12 years, adjusted for inflation at an annual rate of 3%, subject to certain further adjustments. Upon the expiry of the 20-year royalty term, the licenses granted to Mayne Pharma under the Mayne License Agreement will become a fully paid-up and royalty free license for the Licensed Products.

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-9

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-10

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-15

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-13

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Topic 606
-Publisher FASB
-URI https://asc.fasb.org/606/tableOfContent

+ Details

Discontinued Operations (Details) - Schedule of Classes of Assets and Liabilities of Discontinued Operations - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Assets:
Accounts receivable		$ 344
Liabilities:
Accrued expenses and other current liabilities	$ 2,924	$ 3,694

Income (Loss) Per Common Share (Tables)

9 Months Ended

Sep. 30, 2024

Income (Loss) Per Common Share [Abstract]

Schedule of Computation of Basic and Diluted (Loss) Per Common Share

The following table sets forth the computation of basic and diluted (loss) per common share for the periods presented (in thousands, except per share amounts):

	Three Months Ended September 30,						Nine Months Ended September 30,
	2024			2023			2024			2023
Numerator:
Loss from continuing operations, net of income taxes	$	(567	)	$	(1,434	)	$	(2,426	)	$	(6,158	)
Loss from discontinued operations, net of income taxes		(42	)		(1,944	)		(7	)		(3,237	)
Net loss	$	(609	)	$	(3,378	)	$	(2,433	)	$	(9,395	)
Denominator:
Weighted average common shares for basic loss per common share		11,532			10,701			11,532			10,241
Effect of dilutive securities		—			—			—			—
Weighted average common shares for diluted loss per common share		11,532			10,701			11,532			10,241

Loss per common share, continuing operations, net of income taxes
Basic	$	(0.05	)	$	(0.13	)	$	(0.21	)	$	(0.60	)
Diluted	$	(0.05	)	$	(0.13	)	$	(0.21	)	$	(0.60	)
Loss per common share, discontinued operations, net of income taxes
Basic	$	—		$	(0.18	)	$	—		$	(0.32	)
Diluted	$	—		$	(0.18	)	$	—		$	(0.32	)

Schedule of Outstanding Securities

The following table sets forth the outstanding securities as of the periods presented which were not included in the calculation of diluted earnings per common share during the respective three and nine months ended September 30, 2024 and 2023 (in thousands):

	As of September 30,
	2024		2023
Stock options		62		80
RSUs		2		84
PSUs		5		12
Warrants		97		99
		166		275

Prepaid and Other Current Assets

9 Months Ended

Sep. 30, 2024

Prepaid and Other Current Assets [Abstract]

Prepaid and other current assets

3. Prepaid and other current assets

Our prepaid and other current assets consisted of the following as of September 30, 2024 and December 31, 2023 (in thousands):

	September 30, 2024		December 31, 2023
Insurance	$	161	$	253
Capitalized legal		2,334		2,334
Other		1,289		1,448
Prepaid and other current assets	$	3,784	$	4,035

Income (Loss) Per Common Share (Details) - Schedule of Computation of Basic and Diluted (Loss) Per Common Share - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023
Numerator:
Loss from continuing operations, net of income taxes (in Dollars)	$ (567)			$ (1,434)			$ (2,426)	$ (6,158)
Loss from discontinued operations, net of income taxes (in Dollars)	(42)			(1,944)			(7)	(3,237)
Net loss (in Dollars)	$ (609)	$ (1,090)	$ (734)	$ (3,378)	$ (2,414)	$ (3,603)	$ (2,433)	$ (9,395)
Denominator:
Weighted average common shares for basic loss per common share (in Shares)	11,532			10,701			11,532	10,241
Effect of dilutive securities (in Shares)
Weighted average common shares for diluted loss per common share (in Shares)	11,532			10,701			11,532	10,241
Loss per common share, continuing operations, net of income taxes
Basic	$ (0.05)			$ (0.13)			$ (0.21)	$ (0.6)
Diluted	(0.05)			(0.13)			(0.21)	(0.6)
Loss per common share, discontinued operations, net of income taxes
Basic				(0.18)				(0.32)
Diluted				$ (0.18)				$ (0.32)

Accrued Expenses and Other Current Liabilities (Details) - Schedule of Other Accrued Expenses and Other Current Liabilities - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Schedule of Other Accrued Expenses and Other Current Liabilities [Abstract]
Payroll and related costs	$ 455	$ 762
Professional fees	296	489
Operating lease liabilities	1,623	1,473
Other accrued expenses and current liabilities	444	409
Accrued expenses and other current liabilities	$ 2,818	$ 3,133

Revenue (Details)	9 Months Ended
Revenue (Details)	Sep. 30, 2024 USD ($)
Revenue [Line Items]
Period of royalty term	20 years
Mayne License Agreement [Member]
Revenue [Line Items]
Period of royalty term	20 years
Decrease in royalty rate	2.00%
Minimal annual royalty payment	$ 3,000,000
Period of minimal annual royalty payment	12 years
Inflation at an annual rate	3.00%
One-time Milestone Payments [Member] \| Mayne License Agreement [Member]
Revenue [Line Items]
Milestone payments	$ 5,000,000
Net sales	100,000,000
Second-time Milestone Payments [Member] \| Mayne License Agreement [Member]
Revenue [Line Items]
Milestone payments	10,000,000
Net sales	200,000,000
Third-time Milestone Payments [Member] \| Mayne License Agreement [Member]
Revenue [Line Items]
Milestone payments	15,000,000
Net sales	$ 300,000,000
First Royalty Rate [Member] \| Mayne License Agreement [Member]
Revenue [Line Items]
Royalty rate as percentage on net sales	8.00%
Royalties on net sales	$ 80,000,000
Second Royalty Rate [Member] \| Mayne License Agreement [Member]
Revenue [Line Items]
Net sales	$ 80,000,000
Royalty rate as percentage on net sales	7.50%

Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies (Details) - USD ($)				9 Months Ended
	Nov. 15, 2023	Aug. 31, 2023	Jun. 29, 2023	Sep. 30, 2024	Dec. 31, 2023	May 01, 2023
Business, basis of presentation, new accounting standards and summary of significant accounting policies [Line Items]
Period of royalty payments				20 years
Cash payment				$ 140,000,000
Acquisition of net working capital				12,100,000
Cash received for prepaid royalties				1,000,000
Royalty payment				$ 257,000
Quarterly royalty payment, interest per annum				19.00%
Additional fund		$ 1,500,000
Common stock issued (in Shares)				11,532,000	11,532,000
Common stock price per share (in Dollars per share)				$ 0.001	$ 0.001
Mayne License Agreement [Member]
Business, basis of presentation, new accounting standards and summary of significant accounting policies [Line Items]
Period of royalty payments				20 years
Decrease in royalty rate on product-by-product basis				2.00%
Minimal annual royalty payment				$ 3,000,000
Period of minimal annual royalty payment				12 years
Inflation rate adjusted for minimal annual royalty payment				3.00%
Prepaid Royalties				$ 1,000,000
Royalty payment payable under long term service agreement				1,500,000
Royalty payment held		600,000
Additional fund		$ 900,000
Rubric Capital Management L P [Member]
Business, basis of presentation, new accounting standards and summary of significant accounting policies [Line Items]
Common stock issued (in Shares)	877,192					5,000,000
Common stock price per share (in Dollars per share)	$ 2.2761					$ 0.001
Sold shares of common stock (in Shares)			312,525
Price per share (in Dollars per share)			$ 3.6797
Gross proceeds	$ 2,000,000		$ 1,150,000
Milestone Payments One [Member] \| Mayne License Agreement [Member]
Business, basis of presentation, new accounting standards and summary of significant accounting policies [Line Items]
Milestone payments				5,000,000
Net sales amount to determine one-time milestone payment				100,000,000
Milestone Payments Two [Member] \| Mayne License Agreement [Member]
Business, basis of presentation, new accounting standards and summary of significant accounting policies [Line Items]
Milestone payments				10,000,000
Net sales amount to determine one-time milestone payment				200,000,000
Milestone Payments Three [Member] \| Mayne License Agreement [Member]
Business, basis of presentation, new accounting standards and summary of significant accounting policies [Line Items]
Milestone payments				15,000,000
Net sales amount to determine one-time milestone payment				$ 300,000,000
First Royalty Rate [Member] \| Mayne License Agreement [Member]
Business, basis of presentation, new accounting standards and summary of significant accounting policies [Line Items]
Royalty rate as percentage on net sales				8.00%
Threshold annual net sales to determine royalty rate				$ 80,000,000
First Royalty Rate [Member] \| Mayne License Agreement [Member] \| Mayne Pharma [Member]
Business, basis of presentation, new accounting standards and summary of significant accounting policies [Line Items]
Royalty rate as percentage on net sales				8.00%
Threshold annual net sales to determine royalty rate				$ 80,000,000
Second Royalty Rate [Member] \| Mayne License Agreement [Member]
Business, basis of presentation, new accounting standards and summary of significant accounting policies [Line Items]
Net sales amount to determine one-time milestone payment				$ 80,000,000
Royalty rate as percentage on net sales				7.50%
Second Royalty Rate [Member] \| Mayne License Agreement [Member] \| Mayne Pharma [Member]
Business, basis of presentation, new accounting standards and summary of significant accounting policies [Line Items]
Royalty rate as percentage on net sales				7.50%
Threshold annual net sales to determine royalty rate				$ 80,000,000

Commitments and Contingencies

9 Months Ended

Sep. 30, 2024

Commitments and Contingencies [Abstract]

Commitments and contingencies

6. Commitments and contingencies

Mayne Pharma Agreement

Mayne Pharma paid us approximately $12.1 million at closing on December 30, 2022, for the acquisition of net working capital, subject to certain adjustments as determined in accordance with the Transaction Agreement. While the Transaction Agreement calls for much of the net working capital to be trued-up shortly after the Closing Date in 2023, for a period of one year following the Closing Date in the case of payer rebates and wholesale distributor fees and two years following the Closing Date in the case for allowance for returns, net working capital amounts will be adjusted to arrive at final net working capital under the Transaction Agreement.

In September 2023, we increased certain accrual estimates including increasing our working capital adjustment accrual by $2.0 million for amounts anticipated to be owed under the Transaction Agreement. In December 2023, we made a $5.5 million payment to Mayne Pharma to settle certain working capital amounts that were required to be trued-up shortly after the Closing Date, excluding the allowance for returns, allowance for payer rebates, and allowance for wholesale distributor fees. Of the $5.5 million, $2.0 million increased the allowance for net working capital allowances remaining to be trued up.

The Company’s estimate of the allowance for payer rebates and wholesale distributor fees was determined in accordance with the Transaction Agreement which establishes the process for the determination of net working capital. In February 2024, the Company received Mayne Pharma’s calculation of allowance for payer rebates and wholesale distributor fees which differed significantly from the Company’s estimate of the allowances. The Company intends to resolve this matter through the dispute resolution process outlined in the Transaction Agreement.

The Company believes its estimated allowances for payer rebates and wholesale distributor fees are reasonable. The timing and outcome of this matter is uncertain at this point. As a result, the Company cannot reasonably estimate a range of loss, and accordingly, the Company has not accrued any additional liability associated with Mayne Pharma’s allowance calculation for payer rebates and wholesale distributor fees.

In addition, the Company has received information from Mayne Pharma pertaining to the allowance for returns that differs from the Company’s estimate of the allowance. As of September 30, 2024, the Company believes no additional accrual is required for amounts that may be owed for the allowance for returns, as the Company cannot reasonably estimate a range of loss. The Company has not recorded any contingent gains or receivables for any such allowances. Management continues to monitor the unresolved and pending net working capital items as changes to estimated amounts owed or amounts due from Mayne Pharma may be material.

Mayne Pharma has also made certain indemnification demands under the Transaction Agreement, which the Company disputes. As of September 30, 2024, the Company believes no additional accrual is required for such claims, as the Company cannot reasonably estimate a range of loss.

Legal proceedings

In February 2020, we received a Paragraph IV certification notice letter (the “IMVEXXY Notice Letter”) regarding an Abbreviated New Drug Application (“ANDA”) submitted to the FDA by Teva Pharmaceuticals USA, Inc. (“Teva”). The ANDA seeks approval from the FDA to commercially manufacture, use, or sell a generic version of the 4 mcg and 10 mcg doses of IMVEXXY. In the IMVEXXY Notice Letter, Teva alleges that TherapeuticsMD patents listed in the FDA’s Orange Book that claim compositions and methods of IMVEXXY (the “IMVEXXY Patents”) are invalid, unenforceable, and/or will not be infringed by Teva’s commercial manufacture, use, or sale of its proposed generic drug product. The IMVEXXY Patents identified in the IMVEXXY Notice Letter expire in 2032 or 2033. In April 2020, we filed a complaint for patent infringement against Teva in the United States District Court for the District of New Jersey arising from Teva’s ANDA filing with the FDA. We are seeking, among other relief, an order that the effective date of any FDA approval of Teva’s ANDA would be a date no earlier than the expiration of the IMVEXXY Patents and equitable relief enjoining Teva from infringing the IMVEXXY Patents. Teva has filed its answer and counterclaim to the complaint, alleging that the IMVEXXY Patents are invalid and not infringed. In July 2021, following a proposal by Teva, the District Court entered an order temporarily staying all proceedings in the IMVEXXY litigation, which order was filed under seal. In September 2021, the District Court made available a public version of the order following the parties’ agreement to a consent motion to redact information Teva contended was confidential. The order provides that the statutory stay that prevents the FDA from granting final approval of the ANDA for 30 months from the date of the IMVEXXY Notice Letter will be extended for the number of days that the stay of the IMVEXXY litigation is in place. The length of the stay of the IMVEXXY litigation is dependent on further action by Teva. We have incurred and recorded legal costs amounting to $2,334 thousand in prepaid expenses and other current assets as of September 30, 2024, for the IMVEXXY Paragraph IV legal proceeding since we believe that we will successfully prevail in this legal proceeding. Upon the successful conclusion of the legal proceeding, the related capitalized legal costs will be reclassified to patents, in license rights and other intangible assets, net, in the accompanying condensed consolidated balance sheets, and such costs will be amortized over the remaining useful life of the patents. If we are unsuccessful in this legal proceeding, then the related capitalized legal costs for this legal preceding and any unamortized IMVEXXY patent costs that were previously capitalized will be immediately expensed in the period in which we become aware of an unsuccessful legal proceeding.

In June 2024, Mayne received a Paragraph IV certification notice letter (the “Sun Notice Letter”) regarding an ANDA submitted to the FDA by Sun Pharma Inc. (“Sun Pharma”). The ANDA seeks approval from the FDA to commercially manufacture, use, or sell a generic version of the 4 mcg and 10 mcg doses of IMVEXXY. In the Sun Notice Letter, Sun Pharma alleges that the IMVEXXY Patents are invalid, unenforceable, and/or will not be infringed by Sun Pharma’s commercial manufacture, use, or sale of its proposed generic drug product. The IMVEXXY Patents identified in the Sun Notice Letter expire in 2032 or 2033. In July 2024, we and Mayne Pharma filed a complaint for patent infringement against Sun Pharma in the United States District Court for the District of New Jersey arising from Sun Pharma’s ANDA filing with the FDA. We are seeking, among other relief, an order that the effective date of any FDA approval of Sun Pharma’s ANDA would be a date no earlier than the expiration of the IMVEXXY Patents and equitable relief enjoining Sun Pharma from infringing the IMVEXXY Patents.

Beginning on December 30, 2022 and per the Mayne License Agreement, Mayne Pharma is responsible for all enforcement of our patents, including the responsibility for and costs of litigation discussed above with respect to Teva and Sun Pharma.

From time to time, we are involved in other litigations and proceedings in the ordinary course of business. We are currently not involved in any other litigations and proceedings that we believe would have a material effect on our condensed consolidated financial condition, results of operations, or cash flows.

Off-balance sheet arrangements

As of September 30, 2024 and December 31, 2023 there were no off-balance sheet arrangements that have had or are reasonably likely to have current or future effects on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that we consider material.

Employment agreements

In connection with our transformation into a pharmaceutical royalty company, the termination of our executive management team (except for Mr. Marlan Walker, our former General Counsel and current Chief Executive Officer) and all other employees was completed by December 30, 2022. Severance obligations for all employees other than executive officers were paid in full in the first quarter of 2023. As of September 30, 2024, we employed one full-time employee primarily engaged in an executive position. We have engaged external consultants who support our relationship with current partners and assist with certain financial, legal, and regulatory matters and the continued wind-down of our historical business operations. In the aggregate, as of September 30, 2024, we have accrued severance liabilities for executive termination obligations of $56 thousand.

Prepaid and Other Current Assets (Details) - Schedule of Prepaid and Other Current Assets - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Prepaid and Other Current Assets [Abstract]
Insurance	$ 161	$ 253
Capitalized legal	2,334	2,334
Other	1,289	1,448
Prepaid and other current assets	$ 3,784	$ 4,035

Discontinued Operations (Tables)

9 Months Ended

Sep. 30, 2024

Discontinued Operations [Abstract]

Schedule of Discontinued Operations

The following table presents results of discontinued operations (in thousands):

	Three Months Ended September 30,						Nine Months Ended September 30,
	2024			2023			2024			2023
Product revenue, net	$	—		$	(833	)	$	—		$	(833	)
General and administrative expenses		42			(39	)		202			296
Total operating expenses		42			(39	)		202			296
Operating loss from discontinued operations		(42	)		(794	)		(202	)		(1,129	)
Other income (expense), net		—			(1,150	)		195			(2,108	)
Total other income (expense), net		—			(1,150	)		195			(2,108	)
Loss from discontinued operations, net of income taxes	$	(42	)	$	(1,944	)	$	(7	)	$	(3,237	)

Schedule of Classes of Assets and Liabilities of Discontinued Operations

The following table presents the carrying amounts of the classes of assets and liabilities of discontinued operations as of September 30, 2024 and December 31, 2023 (in thousands):

	September 30, 2024		December 31, 2023
Assets:
Accounts receivable	$	-	$	344
Liabilities:
Accrued expenses and other current liabilities	$	2,924	$	3,694

- Definition

Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-SubTopic 10
-Topic 360
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482099/360-10-50-3

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 45
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483475/205-20-45-11

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 3A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-3A

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-4A

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-4B

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5D
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-5D

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 360
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482099/360-10-50-3A

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-SubTopic 20
-Topic 205
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-1

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-3

+ Details

Condensed Consolidated Balance Sheets (Parentheticals) - $ / shares	Sep. 30, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	32,000,000	32,000,000
Common stock, shares issued	11,532,000	11,532,000
Common stock, shares outstanding	11,532,000	11,532,000

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Operating expenses:
Selling, general and administrative	$ 1,310	$ 1,590	$ 3,865	$ 7,427
Impairment of long-lived assets (Note 4)			1,261
Depreciation & amortization	96	130	409	285
Total operating expenses	1,406	1,720	5,535	7,712
Loss from operations	(859)	(1,773)	(4,441)	(6,912)
Other income (expense):
Interest expense and other financing costs	(3)	(20)	(8)	(115)
Miscellaneous income	295	359	2,023	869
Total other income, net	292	339	2,015	754
Loss from continuing operations before income taxes	(567)	(1,434)	(2,426)	(6,158)
Provision for income taxes
Loss from continuing operations, net of income taxes	(567)	(1,434)	(2,426)	(6,158)
Loss from discontinued operations, net of income taxes	(42)	(1,944)	(7)	(3,237)
Net loss	$ (609)	$ (3,378)	$ (2,433)	$ (9,395)
Loss per common share, basic and diluted:
Continuing operations, basic (in Dollars per share)	$ (0.05)	$ (0.13)	$ (0.21)	$ (0.6)
Continuing operations, diluted (in Dollars per share)	(0.05)	(0.13)	(0.21)	(0.6)
Discontinued operations, net basic (in Dollars per share)		(0.18)		(0.32)
Discontinued operations, net diluted (in Dollars per share)		(0.18)		(0.32)
Net loss per common share, basic (in Dollars per share)	(0.05)	(0.32)	(0.21)	(0.92)
Net loss per common share, diluted (in Dollars per share)	$ (0.05)	$ (0.32)	$ (0.21)	$ (0.92)
Weighted average common shares, basic (in Shares)	11,532	10,701	11,532	10,241
Weighted average common shares, diluted (in Shares)	11,532	10,701	11,532	10,241
License and service revenue
Revenue, net:
License and service revenue	$ 547	$ (53)	$ 1,094	$ 800

Business Concentrations (Details) $ in Thousands	3 Months Ended	9 Months Ended
Business Concentrations (Details) $ in Thousands	Sep. 30, 2024 USD ($)	Sep. 30, 2024 USD ($)
Theramex [Member]
Business Concentrations [Line Items]
Customer license revenue percentage	100.00%	100.00%
Mayne Pharma [Member]
Business Concentrations [Line Items]
Royalty receivable short term portion	$ 3,323	$ 3,323
Royalty receivable long term portion	$ 16,610	$ 16,610

Licensed Rights and Other Intangible Assets (Details) - Patents [Member] - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Licensed Rights and Other Intangible Assets [Line Items]
Amortization expense	$ 96	$ 110	$ 409	$ 227
Impairment loss			$ 1,261

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References + Details

Stockholders’ Equity (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
Stockholders’ Equity (Details) - USD ($)	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2022
Stockholders’ Equity [Line Items]
Total unrecognized share based compensation	$ 48,000		$ 48,000
Unrecognized compensation cost	$ 48,000		$ 48,000
Share-based compensation over a weighted average period			6 months
Phantom Share Units (PSUs) [Member]
Stockholders’ Equity [Line Items]
Number of shares outstanding (in Shares)	61,530		61,530
Vesting percentage					100.00%
Employee Stock Purchase Plan [Member]
Stockholders’ Equity [Line Items]
Share based payment compensation expense	$ 33,000	$ 234,000	$ 240,000	$ 1,155,000
2019 Stock Incentive Plan [Member]
Stockholders’ Equity [Line Items]
Remaining shares of common stock available for future issuance (in Shares)	405,719		405,719

Cover - shares	9 Months Ended
Cover - shares	Sep. 30, 2024	Nov. 11, 2024
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Transition Report	false
Entity Interactive Data Current	Yes
Amendment Flag	false
Document Period End Date	Sep. 30, 2024
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q3
Entity Information [Line Items]
Entity Registrant Name	TherapeuticsMD, Inc.
Entity Central Index Key	0000025743
Entity File Number	001-00100
Entity Tax Identification Number	87-0233535
Entity Incorporation, State or Country Code	NV
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Contact Personnel [Line Items]
Entity Address, Address Line One	951 Yamato Road
Entity Address, Address Line Two	Suite 220
Entity Address, City or Town	Boca Raton
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33431
Entity Phone Fax Numbers [Line Items]
City Area Code	561
Local Phone Number	961-1900
Entity Listings [Line Items]
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	TXMD
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding		11,532,432

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Sep. 30, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Income (Loss) Per Common Share

9 Months Ended

Sep. 30, 2024

Income (Loss) Per Common Share [Abstract]

Income (Loss) per common share

10. Income (Loss) per common share

The following table sets forth the computation of basic and diluted (loss) per common share for the periods presented (in thousands, except per share amounts):

	Three Months Ended September 30,						Nine Months Ended September 30,
	2024			2023			2024			2023
Numerator:
Loss from continuing operations, net of income taxes	$	(567	)	$	(1,434	)	$	(2,426	)	$	(6,158	)
Loss from discontinued operations, net of income taxes		(42	)		(1,944	)		(7	)		(3,237	)
Net loss	$	(609	)	$	(3,378	)	$	(2,433	)	$	(9,395	)
Denominator:
Weighted average common shares for basic loss per common share		11,532			10,701			11,532			10,241
Effect of dilutive securities		—			—			—			—
Weighted average common shares for diluted loss per common share		11,532			10,701			11,532			10,241

Loss per common share, continuing operations, net of income taxes
Basic	$	(0.05	)	$	(0.13	)	$	(0.21	)	$	(0.60	)
Diluted	$	(0.05	)	$	(0.13	)	$	(0.21	)	$	(0.60	)
Loss per common share, discontinued operations, net of income taxes
Basic	$	—		$	(0.18	)	$	—		$	(0.32	)
Diluted	$	—		$	(0.18	)	$	—		$	(0.32	)

Since we reported a net loss from continuing operations for the three and nine months ended September 30, 2024 and 2023, our potentially dilutive securities are deemed to be anti-dilutive, accordingly, there was no effect of dilutive securities. Therefore, our basic and diluted loss per common share and our basic and diluted weighted average common shares are the same for the three and nine months ended September 30, 2024 and 2023.

	As of September 30,
	2024		2023
Stock options		62		80
RSUs		2		84
PSUs		5		12
Warrants		97		99
		166		275

Prepaid and Other Current Assets (Tables)

9 Months Ended

Sep. 30, 2024

Prepaid and Other Current Assets [Abstract]

Schedule of Prepaid and Other Current Assets

Our prepaid and other current assets consisted of the following as of September 30, 2024 and December 31, 2023 (in thousands):

	September 30, 2024		December 31, 2023
Insurance	$	161	$	253
Capitalized legal		2,334		2,334
Other		1,289		1,448
Prepaid and other current assets	$	3,784	$	4,035

Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2024

Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies [Abstract]

Business, basis of presentation, new accounting standards and summary of significant accounting policies

1. Business, basis of presentation, new accounting standards and summary of significant accounting policies

General

We also have license agreements with strategic partners to commercialize IMVEXXY and BIJUVA outside of the U.S.

●

Going concern

The accompanying consolidated financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern.

Basis of presentation

New accounting standards

Adoption of new accounting standards

Estimates and assumptions

Significant accounting policies

The significant accounting policies we use for quarterly financial reporting are disclosed in Note 1 of the notes to the consolidated financial statements included in our 2023 10-K report.

Income (Loss) Per Common Share (Details) - Schedule of Outstanding Securities - shares shares in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Schedule of Outstanding Securities [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	166	275
Stock options [Member]
Schedule of Outstanding Securities [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	62	80
RSUs [Member]
Schedule of Outstanding Securities [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2	84
PSUs [Member]
Schedule of Outstanding Securities [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	5	12
Warrants [Member]
Schedule of Outstanding Securities [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	97	99

Commitments and Contingencies (Details) - USD ($) $ in Thousands		9 Months Ended	12 Months Ended
	Sep. 30, 2023	Sep. 30, 2024	Dec. 30, 2022	Dec. 31, 2023
Mayne Pharma Agreement [Member]
Commitments and Contingencies [Line Items]
Cash Received For Net Working Capital			$ 12,100
Incremental accrual for net working capital	$ 2,000
Working capital amounts				$ 5,500
Maximum [Member]
Commitments and Contingencies [Line Items]
Allowance for net working capital allowances remaining				5,500
Minimum [Member]
Commitments and Contingencies [Line Items]
Allowance for net working capital allowances remaining				$ 2,000
Chief Executive Officer [Member]
Commitments and Contingencies [Line Items]
Executive termination obligations		$ 56
Paragraph IV Certification Notice Letter [Member]
Commitments and Contingencies [Line Items]
Legal costs		$ 2,334

Licensed Rights and Other Intangible Assets (Details) - Schedule of License Rights and Other Intangible Assets, Net - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Schedule of License Rights and Other Intangible Assets, Net [Line Items]
Gross Carrying Amount	$ 6,385	$ 7,969
Accumulated Amortization	1,957	1,871
Net	4,428	6,098
Hormone therapy drug patents [Member]
Schedule of License Rights and Other Intangible Assets, Net [Line Items]
Gross Carrying Amount	5,753	6,818
Accumulated Amortization	1,957	1,871
Net	3,796	4,947
Hormone therapy drug patents applied and pending approval [Member]
Schedule of License Rights and Other Intangible Assets, Net [Line Items]
Gross Carrying Amount	323	842
Accumulated Amortization
Net	323	842
Intangible assets subject to amortization [Member]
Schedule of License Rights and Other Intangible Assets, Net [Line Items]
Gross Carrying Amount	6,076	7,660
Accumulated Amortization	1,957	1,871
Net	4,119	5,789
Trademarks/trade name rights [Member]
Schedule of License Rights and Other Intangible Assets, Net [Line Items]
Gross Carrying Amount	309	309
Accumulated Amortization
Net	$ 309	$ 309

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References + Details

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 5,047	$ 4,327
Royalty receivable, current portion	3,323	3,090
Prepaid and other current assets	3,784	4,035
Current assets of discontinued operations		344
Total current assets	12,154	11,796
License rights and other intangible assets, net	4,428	6,098
Right of use assets	6,302	6,873
Royalty receivable, long term	16,610	18,484
Other non-current assets	58	58
Total assets	39,552	43,309
Current liabilities:
Accounts payable	234	27
Accrued expenses and other current liabilities	2,818	3,133
Current liabilities of discontinued operations	2,924	3,694
Total current liabilities	5,976	6,854
Operating lease liabilities	5,777	6,532
Other non-current liabilities	705	636
Total liabilities	12,458	14,022
Commitments and contingencies (Note 6)
Stockholders' equity:
Common stock, par value $0.001; 32,000 shares authorized, 11,532 issued and outstanding as of September 30, 2024 and December 31, 2023	11	11
Additional paid-in capital	979,157	978,917
Accumulated deficit	(952,074)	(949,641)
Total stockholders' equity	27,094	29,287
Total liabilities and stockholders' equity	$ 39,552	$ 43,309

Income Taxes (Details) - USD ($)	3 Months Ended		9 Months Ended
Income Taxes (Details) - USD ($)	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Income Taxes [Abstract]
Provisions for income taxes

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-10

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Subparagraph (a)
-SubTopic 20
-Topic 740
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482659/740-20-45-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-SubTopic 10
-Topic 235
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

+ Details

Stockholders’ Equity (Details) - Schedule of Status of Our Outstanding and Exercisable Warrants - Warrant [Member] shares in Thousands	9 Months Ended
	Sep. 30, 2024 USD ($) $ / shares shares
Schedule of Status of Our Outstanding and Exercisable Warrants [Line Items]
Beginning Balance \| shares	99
Weighted Average Exercise Price, Beginning Balance \| $ / shares	$ 66.61
Aggregate Intrinsic Value, Beginning Balance \| $
Weighted Average Remaining Contractual Life, Beginning Balance	6 years 6 months
Expired, Warrants \| shares	(2)
Expired, Weighted Average Exercise Price \| $ / shares	$ 281.5
Expired, Aggregate Intrinsic Value \| $
Expired, Weighted Average Remaining Contractual Life
Ending Balance \| shares	97
Weighted Average Exercise Price, Ending Balance \| $ / shares	$ 63.33
Aggregate Intrinsic Value, Ending Balance \| $
Weighted Average Remaining Contractual Life, Ending Balance	5 years 9 months 18 days

Related Parties (Details) - USD ($) $ / shares in Units, $ in Thousands	Jun. 29, 2023	Dec. 30, 2022	Sep. 30, 2024	Dec. 31, 2023	Nov. 15, 2023
Related Parties [Line Items]
Subscription agreements payment		$ 3,000
Common stock shares			11,532,000	11,532,000
Rubric [Member]
Related Parties [Line Items]
Preferred stock at a purchase price	$ 3.6797
Common stock shares	312,525
Gross proceeds	$ 1,150
Additional shares of common stock					877,192
Price per shares					$ 2.2761
Gross proceeds from drawdown before expenses					$ 2,000
Series A Preferred Stock [Member] \| Rubric [Member] \| Subscription Agreement [Member]
Related Parties [Line Items]
Outstanding shares		29,000
Preferred stock at a purchase price		$ 1,333

Stockholders’ Equity

9 Months Ended

Sep. 30, 2024

Stockholders’ Equity [Abstract]

Stockholders’ equity

7. Stockholders’ equity

Warrants

As of September 30, 2024, the following table summarizes the status of our outstanding and exercisable warrants and related transactions since December 31, 2023 (in thousands, except weighted average exercise price and weighted average remaining contractual life data):

	Warrants Outstanding and exercisable
	Warrants			Weighted Average Exercise Price		Aggregate Intrinsic Value		Weighted Average Remaining Contractual Life (in Years)
As of January 1, 2024		99		$	66.61	$	—		6.5
Expired		(2	)		281.50		—		—
As of September 30, 2024		97		$	63.33	$	—		5.8

Share-based compensation payment plans

As of September 30, 2024, 61,530 shares of common stock were subject to outstanding awards under our share-based payment award plans and inducement grants (calculated using the base number of PSUs that may vest). As of September 30, 2024, 405,719 shares of common stock were available for future grants of share-based payment awards under the TherapeuticsMD, Inc. 2019 Stock Incentive Plan.

The following table summarizes the status of our outstanding and exercisable options and related transactions since December 31, 2023 (in thousands, except weighted average exercise price and weighted average remaining contractual life data):

	Outstanding									Exercisable
	Options Awards			Weighted Average Exercise Price		Aggregate Intrinsic Value		Weighted Average Remaining Contractual Life (in Years)		Options Awards			Weighted Average Exercise Price		Aggregate Intrinsic Value		Weighted Average Remaining Contractual Life (in Years)
As of January 1, 2024		72		$	258.55	$	—		3.0		72		$	258.46	$	—		3.0
Expired		(10	)		224.58		—		—		(10	)		—		—		—
As of September 30, 2024		62		$	264.66	$	—		2.8		62		$	264.54	$	—		2.8

The following table summarizes the status of our RSUs and related transactions since December 31, 2023 (in thousands, except weighted average grant date fair value):

	RSUs awards outstanding
	RSUs			Weighted Average Grant Date Fair Value		Aggregate Intrinsic Value
As of January 1, 2024		40		$	9.67	$	89.60
Vested		(38	)		9.11		—
As of September 30, 2024		2		$	21.78	$	2.88

The following table summarizes the status of our PSUs and related transactions since December 31, 2023 (in thousands, except weighted average grant date fair value):

	Outstanding
	PSUs ⁽¹⁾			Weighted Average Grant Date Fair Value		Aggregate Intrinsic Value
Unvested, as of January 1, 2024		12		$	49.36	$	32.57
Vested		(7	)		60.50		16.16
Unvested, as of September 30, 2024		5		$	34.50	$	8.63

(1)	The number of PSUs represents the base number of PSUs that may vest.

Share-based payment compensation cost

Share-based payment compensation expense for PSUs is based on 100% vesting which was a part of the termination benefits for all employees who were terminated in 2022. We recorded share-based payment award compensation costs related to previously issued options, RSU and PSUs, as well as shares of common stock issued under our employee stock purchase plan (“ESPP”) totaling $33 thousand and $234 thousand for the three months ended September 30, 2024 and 2023, respectively, and $240 thousand and $1,155 thousand for the nine months ended September 30, 2024 and 2023, respectively.

As of September 30, 2024, we had $48 thousand of unrecognized share-based payment award compensation cost related to unvested options, RSUs and PSUs as well as shares issuable under our ESPP, which may be adjusted for future changes in forfeitures and is included as additional paid-in capital in the accompanying condensed consolidated balance sheets. No tax benefit was realized due to a continued pattern of net losses. The unrecognized compensation cost of $48 thousand is expected to be recognized as share-based payment award compensation over a weighted average period of 0.5 years.

Stockholders’ Equity (Tables)

9 Months Ended

Sep. 30, 2024

Stockholders’ Equity [Abstract]

Schedule of Status of Our Outstanding and Exercisable Warrants

	Warrants Outstanding and exercisable
	Warrants			Weighted Average Exercise Price		Aggregate Intrinsic Value		Weighted Average Remaining Contractual Life (in Years)
As of January 1, 2024		99		$	66.61	$	—		6.5
Expired		(2	)		281.50		—		—
As of September 30, 2024		97		$	63.33	$	—		5.8

Schedule of Status of Our Outstanding and Exercisable Options and Related Transactions

	Outstanding									Exercisable
	Options Awards			Weighted Average Exercise Price		Aggregate Intrinsic Value		Weighted Average Remaining Contractual Life (in Years)		Options Awards			Weighted Average Exercise Price		Aggregate Intrinsic Value		Weighted Average Remaining Contractual Life (in Years)
As of January 1, 2024		72		$	258.55	$	—		3.0		72		$	258.46	$	—		3.0
Expired		(10	)		224.58		—		—		(10	)		—		—		—
As of September 30, 2024		62		$	264.66	$	—		2.8		62		$	264.54	$	—		2.8

Schedule of the Status of Our RSUs, and Related Transactions

The following table summarizes the status of our RSUs and related transactions since December 31, 2023 (in thousands, except weighted average grant date fair value):

	RSUs awards outstanding
	RSUs			Weighted Average Grant Date Fair Value		Aggregate Intrinsic Value
As of January 1, 2024		40		$	9.67	$	89.60
Vested		(38	)		9.11		—
As of September 30, 2024		2		$	21.78	$	2.88

Schedule of the Status of Our PSUs and Related Transactions

The following table summarizes the status of our PSUs and related transactions since December 31, 2023 (in thousands, except weighted average grant date fair value):

	Outstanding
	PSUs ⁽¹⁾			Weighted Average Grant Date Fair Value		Aggregate Intrinsic Value
Unvested, as of January 1, 2024		12		$	49.36	$	32.57
Vested		(7	)		60.50		16.16
Unvested, as of September 30, 2024		5		$	34.50	$	8.63

(1)	The number of PSUs represents the base number of PSUs that may vest.

Stockholders’ Equity (Details) - Schedule of Status of Our Outstanding and Exercisable Options and Related Transactions - USD ($) shares in Thousands		9 Months Ended
	Jan. 01, 2024	Sep. 30, 2024
Schedule of Stock Options Activity [Abstract]
Options Awards Outstanding, Ending Balance	72	62
Weighted Average Exercise Price Outstanding, Ending Balance	$ 258.55	$ 264.66
Aggregate Intrinsic Value Outstanding, Ending Balance
Weighted Average Remaining Contractual Life (in Years) Outstanding, Ending Balance	3 years	2 years 9 months 18 days
Options Awards Exercisable, Ending Balance	72	62
Weighted Average Exercise Price Exercisable, Ending Balance	$ 258.46	$ 264.54
Aggregate Intrinsic Value Exercisable, Ending Balance
Weighted Average Remaining Contractual Life (in Years) Exercisable, Ending Balance	3 years	2 years 9 months 18 days
Options Awards Outstanding, Expired		(10)
Weighted Average Exercise Price Outstanding, Expired		$ 224.58
Aggregate Intrinsic Value Outstanding, Expired
Options Awards Exercisable, Expired		(10)
Weighted Average Exercise Price Exercisable, Expired
Aggregate Intrinsic Value Exercisable, Expired

Stockholders’ Equity (Details) - Schedule of the Status of Our RSUs, and Related Transactions - Restricted Stock Units (RSUs) [Member]	9 Months Ended
	Sep. 30, 2024 USD ($) $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Beginning Balance \| shares	40,000
Weighted Average Exercise Price, Beginning Balance \| $ / shares	$ 9.67
Aggregate Intrinsic Value, Beginning Balance \| $	$ 89,600
RSUs, Vested \| shares	(38,000)
Weighted Average Grant Date Fair Value Vested \| $ / shares	$ 9.11
Aggregate Intrinsic Value Vested \| $
Ending Balance \| shares	2,000
Weighted Average Exercise Price, Ending Balance \| $ / shares	$ 21.78
Aggregate Intrinsic Value, Ending Balance \| $	$ 2,880

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

+ Details

Discontinued Operations

9 Months Ended

Sep. 30, 2024

Discontinued Operations [Abstract]

Discontinued Operations

2. Discontinued Operations

As discussed in Note 1, we changed our business in 2022 by licensing our products to receive royalties and future sales related milestone payments, after granting an exclusive license to commercialize our IMVEXXY, BIJUVA, and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands in the United States and assigning our exclusive license to commercialize ANNOVERA to Mayne Pharma.

This plan represented a strategic shift having a major effect on our operations and financial results. Upon our conversion from a commercial pharmaceutical company to a licensing only company with the consummation of the Mayne Transaction, we classified all direct revenues, costs and expenses related to commercial operations, within income (loss) from discontinued operations, net of tax, in the condensed consolidated statements of operations for all periods presented. We have not allocated any amounts for shared general and administrative operating support expense to discontinued operations.

Additionally, the related assets and liabilities have been reported as assets and liabilities of discontinued operations in our condensed consolidated balance sheets as of September 30, 2024 and December 31, 2023.

As described in Note 1, the acquisition of net working capital by Mayne Pharma was determined in accordance with the Transaction Agreement and included significant estimates which could change materially for a period of up to two years following the Closing Date. Our estimate of net working capital at closing was determined in accordance with the Transaction Agreement which establishes the process for the determination of final net working capital. Refer to Note 6 for a further discussion of net working capital contingencies.

The following table presents results of discontinued operations (in thousands):

	Three Months Ended September 30,						Nine Months Ended September 30,
	2024			2023			2024			2023
Product revenue, net	$	—		$	(833	)	$	—		$	(833	)
General and administrative expenses		42			(39	)		202			296
Total operating expenses		42			(39	)		202			296
Operating loss from discontinued operations		(42	)		(794	)		(202	)		(1,129	)
Other income (expense), net		—			(1,150	)		195			(2,108	)
Total other income (expense), net		—			(1,150	)		195			(2,108	)
Loss from discontinued operations, net of income taxes	$	(42	)	$	(1,944	)	$	(7	)	$	(3,237	)

The following table presents the carrying amounts of the classes of assets and liabilities of discontinued operations as of September 30, 2024 and December 31, 2023 (in thousands):

	September 30, 2024		December 31, 2023
Assets:
Accounts receivable	$	-	$	344
Liabilities:
Accrued expenses and other current liabilities	$	2,924	$	3,694

Accrued Expenses and Other Current Liabilities (Tables)

9 Months Ended

Sep. 30, 2024

Accrued Expenses and Other Current Liabilities [Abstract]

Schedule of Other Accrued Expenses and Other Current Liabilities

Other accrued expenses and other current liabilities consisted of the following (in thousands):

	September 30, 2024		December 31, 2023
Payroll and related costs	$	455	$	762
Professional fees		296		489
Operating lease liabilities		1,623		1,473
Other accrued expenses and current liabilities		444		409
Accrued expenses and other current liabilities	$	2,818	$	3,133

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
Pay vs Performance Disclosure - USD ($) $ in Thousands	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023
Pay vs Performance Disclosure
Net Income (Loss)	$ (609)	$ (1,090)	$ (734)	$ (3,378)	$ (2,414)	$ (3,603)	$ (2,433)	$ (9,395)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 17: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-10

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479105/946-220-45-7

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7

Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B

Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

+ Details

Discontinued Operations (Details) - Schedule of Discontinued Operations - Discontinued Operations [Member] - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Schedule of Discontinued Operations [Line Items]
Product revenue, net		$ (833)		$ (833)
General and administrative expenses	42	(39)	202	296
Total operating expenses	42	(39)	202	296
Operating loss from discontinued operations	(42)	(794)	(202)	(1,129)
Other income (expense), net		(1,150)	195	(2,108)
Total other income (expense), net		(1,150)	195	(2,108)
Loss from discontinued operations, net of income taxes	$ (42)	$ (1,944)	$ (7)	$ (3,237)

- Definition

Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(12))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 45
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477349/740-270-45-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 45
-Paragraph 3A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483475/205-20-45-3A

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5C
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 45
-Paragraph 3B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483475/205-20-45-3B

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 45
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483475/205-20-45-4

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-1

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 45
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483475/205-20-45-3

+ Details

Condensed Consolidated Statements of Stockholders’ Equity (Unaudited) - USD ($) $ in Thousands	Common Stock	Additional Paid in Capital	Accumulated Deficit	Total
Balance at Dec. 31, 2022	$ 9	$ 974,497	$ (939,363)	$ 35,143
Balance (in Shares) at Dec. 31, 2022	9,498,000
Shares issued for vested restricted stock units	$ 1			1
Shares issued for vested restricted stock units (in Shares)	455,000
Share-based compensation		483		483
Net loss			(3,603)	(3,603)
Balance at Mar. 31, 2023	$ 10	974,980	(942,966)	32,024
Balance (in Shares) at Mar. 31, 2023	9,953,000
Balance at Dec. 31, 2022	$ 9	974,497	(939,363)	35,143
Balance (in Shares) at Dec. 31, 2022	9,498,000
Net loss				(9,395)
Balance at Sep. 30, 2023	$ 11	976,799	(948,758)	28,052
Balance (in Shares) at Sep. 30, 2023	10,575,000
Balance at Mar. 31, 2023	$ 10	974,980	(942,966)	32,024
Balance (in Shares) at Mar. 31, 2023	9,953,000
Shares issued for vested restricted stock units
Shares issued for vested restricted stock units (in Shares)	60,000
Shares issued for sale of common stock related to private placement sale	$ 1	1,149		1,150
Shares issued for sale of common stock related to private placement sale (in Shares)	313,000
Share-based compensation		437		437
Shares issued for exercise of warrants
Shares issued for exercise of warrants (in Shares)	249,000
Net loss			(2,414)	(2,414)
Balance at Jun. 30, 2023	$ 11	976,566	(945,380)	31,197
Balance (in Shares) at Jun. 30, 2023	10,575,000
Share-based compensation		233		233
Net loss			(3,378)	(3,378)
Balance at Sep. 30, 2023	$ 11	976,799	(948,758)	28,052
Balance (in Shares) at Sep. 30, 2023	10,575,000
Balance at Dec. 31, 2023	$ 11	978,917	(949,641)	$ 29,287
Balance (in Shares) at Dec. 31, 2023	11,532,000			11,532,000
Share-based compensation		111		$ 111
Net loss			(734)	(734)
Balance at Mar. 31, 2024	$ 11	979,028	(950,375)	28,664
Balance (in Shares) at Mar. 31, 2024	11,532,000
Balance at Dec. 31, 2023	$ 11	978,917	(949,641)	$ 29,287
Balance (in Shares) at Dec. 31, 2023	11,532,000			11,532,000
Net loss				$ (2,433)
Balance at Sep. 30, 2024	$ 11	979,157	(952,074)	$ 27,094
Balance (in Shares) at Sep. 30, 2024	11,532,000			11,532,000
Balance at Mar. 31, 2024	$ 11	979,028	(950,375)	$ 28,664
Balance (in Shares) at Mar. 31, 2024	11,532,000
Share-based compensation		96		96
Net loss			(1,090)	(1,090)
Balance at Jun. 30, 2024	$ 11	979,124	(951,465)	27,670
Balance (in Shares) at Jun. 30, 2024	11,532,000
Share-based compensation		33		33
Net loss			(609)	(609)
Balance at Sep. 30, 2024	$ 11	$ 979,157	$ (952,074)	$ 27,094
Balance (in Shares) at Sep. 30, 2024	11,532,000			11,532,000

Licensed Rights and Other Intangible Assets

9 Months Ended

Sep. 30, 2024

Licensed Rights and Other Intangible Assets [Abstract]

Licensed rights and other intangible assets

4. Licensed rights and other intangible assets

The following provides information about our license rights and other intangible assets, net as of September 30, 2024 and December 31, 2023 (in thousands):

	September 30, 2024						December 31, 2023
	Gross Carrying Amount		Accumulated Amortization		Net		Gross Carrying Amount		Accumulated Amortization		Net
Intangible assets subject to amortization:
Hormone therapy drug patents	$	5,753	$	1,957	$	3,796	$	6,818	$	1,871	$	4,947
Hormone therapy drug patents applied and pending approval		323		—		323		842		—		842
Intangible assets subject to amortization		6,076		1,957		4,119		7,660		1,871		5,789
Intangible assets not subject to amortization:
Trademarks/trade name rights		309		—		309		309		—		309
License rights and other intangible assets, net	$	6,385	$	1,957	$	4,428	$	7,969	$	1,871	$	6,098

We recorded, in continuing operations, amortization expense related to patents of $96 thousand and $110 thousand for the three months ended September 30, 2024 and 2023, respectively, and $409 thousand and $227 thousand for the nine months ended September 30, 2024 and 2023, respectively.

The Company conducts regular reviews of the individual patents and portfolios. As a result of this review, also based on input from its licensing partners in the three months ended June 30, 2024, the Company determined it had an indicator of impairment, as it had abandoned the legal right and title to a portion of its granted patent portfolio and had ceased pursuit of a portion of its pending patents based on input from its licensing partners. The Company recognized an impairment loss of $1,261 thousand related to those abandoned patents and applications, which is classified as an impairment of long-lived assets on the Company’s condensed consolidated statements of operations for the nine months ended September 30, 2024.

Our intangible assets subject to amortization are expected to be amortized as follows (in thousands):

Year ending December 31,
2024	$	97
2025		384
2026		384
2027		384
2028		384
Thereafter		2,163
Total	$	3,796

Related Parties

9 Months Ended

Sep. 30, 2024

Related Parties [Abstract]

Related parties

11. Related parties

On August 23, 2022, we appointed Mr. Justin Roberts as a director to fill a newly created vacancy on our Board of Directors. Mr. Roberts was elected to serve as a director at our combined 2022 and 2023 Annual Meeting held on June 26, 2023. Mr. Roberts will serve until our next Annual Meeting of Stockholders or until his successor is duly elected or appointed or his earlier death or resignation. As a director of our Company, Mr. Roberts is entitled to receive compensation in the same manner as our other non-employee directors, described in the section entitled “Director Compensation” in our Amendment No. 1 to Form 10-K for the fiscal year ended December 31, 2023, filed with the Securities and Exchange Commission on April 29, 2024, but he has elected not to receive any compensation for his service as a non-employee director at this time. Mr. Roberts currently serves as a Partner of Rubric. On July 29, 2022, September 30, 2022, October 28, 2022, and May 1, 2023, we entered into subscription agreements with Rubric. On December 30, 2022, in accordance with the terms of the Certificate of Designation, we redeemed all 29,000 outstanding shares of Series A Preferred Stock previously issued to affiliates of Rubric at a purchase price of $1,333 per share and also paid certain affiliates of Rubric approximately $3.0 million as a make-whole payment pursuant to the subscription agreements previously entered into between us and Rubric. On June 29, 2023, we issued and sold 312,525 shares of Common Stock to Rubric at a price per share equal to $3.6797 pursuant to the Subscription Agreement and received gross proceeds of $1.15 million, before expenses. On November 15, 2023 Rubric drew down an additional 877,192 shares of Common Stock at a price per share equal to $2.2761. We received gross proceeds of $2.0 million from the drawdown, before expenses.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-5

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-6

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(g)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(e))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/850/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-6

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

+ Details

Accrued Expenses and Other Current Liabilities

9 Months Ended

Sep. 30, 2024

Accrued Expenses and Other Current Liabilities [Abstract]

Accrued expenses and other current liabilities

5. Accrued expenses and other current liabilities

Other accrued expenses and other current liabilities consisted of the following (in thousands):

	September 30, 2024		December 31, 2023
Payroll and related costs	$	455	$	762
Professional fees		296		489
Operating lease liabilities		1,623		1,473
Other accrued expenses and current liabilities		444		409
Accrued expenses and other current liabilities	$	2,818	$	3,133